Shares of Pain Therapeutics (NASDAQ:PTIE) were up 2.1% on Friday . The stock traded as high as $2.41 and last traded at $2.41, with a volume of 52,550 shares traded. The stock had previously closed at $2.36.

Separately, Zacks Investment Research upgraded Pain Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The firm has a 50 day moving average of $2.49 and a 200-day moving average of $2.24. The firm’s market capitalization is $112.12 million.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.07. Analysts predict that Pain Therapeutics will post ($0.42) EPS for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.